These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 34978890)

  • 1. Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the
    Jeffrey JL; St Clair M; Wang P; Wang C; Li Z; Beloor J; Talarico C; Fridell R; Krystal M; White CT; Griffith S; D'Amico R; Smith K; Van Eygen V; Vingerhoets J; Vandermeulen K; Spreen W; van Lunzen J
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0170221. PubMed ID: 34978890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the L74I Polymorphism on Fitness of Cabotegravir-Resistant Variants of Human Immunodeficiency Virus 1 Subtype A6.
    Hu Z; Cordwell T; Nguyen H; Li J; Jeffrey JL; Kuritzkes DR
    J Infect Dis; 2023 Nov; 228(10):1352-1356. PubMed ID: 37497681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency of genotypic factors possibly associated with cabotegravir/rilpivirine failure in antiretroviral treatment-naïve and -experienced HIV-1- infected population.
    Scheibe K; Urbańska A; Serwin K; Parczewski M
    Infect Genet Evol; 2022 Oct; 104():105358. PubMed ID: 36057423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patients.
    Charpentier C; Storto A; Soulié C; Ferré VM; Wirden M; Joly V; Lambert-Niclot S; Palich R; Morand-Joubert L; Landman R; Lacombe K; Katlama C; Ghosn J; Marcelin AG; Calvez V; Descamps D
    J Antimicrob Chemother; 2021 Oct; 76(11):2983-2987. PubMed ID: 34015097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
    Orkin C; Oka S; Philibert P; Brinson C; Bassa A; Gusev D; Degen O; García JG; Morell EB; Tan DHS; D'Amico R; Dorey D; Griffith S; Thiagarajah S; St Clair M; Van Solingen-Ristea R; Crauwels H; Ford SL; Patel P; Chounta V; Vanveggel S; Cutrell A; Van Eygen V; Vandermeulen K; Margolis DA; Smith KY; Spreen WR
    Lancet HIV; 2021 Apr; 8(4):e185-e196. PubMed ID: 33794181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
    Margolis DA; Gonzalez-Garcia J; Stellbrink HJ; Eron JJ; Yazdanpanah Y; Podzamczer D; Lutz T; Angel JB; Richmond GJ; Clotet B; Gutierrez F; Sloan L; Clair MS; Murray M; Ford SL; Mrus J; Patel P; Crauwels H; Griffith SK; Sutton KC; Dorey D; Smith KY; Williams PE; Spreen WR
    Lancet; 2017 Sep; 390(10101):1499-1510. PubMed ID: 28750935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future of long-acting cabotegravir plus rilpivirine therapy: deeds and misconceptions.
    Rusconi S; Santoro MM; Capetti AF; Gianotti N; Zazzi M
    Int J Antimicrob Agents; 2022 Sep; 60(3):106627. PubMed ID: 35760225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.
    Orkin C; Bernal Morell E; Tan DHS; Katner H; Stellbrink HJ; Belonosova E; DeMoor R; Griffith S; Thiagarajah S; Van Solingen-Ristea R; Ford SL; Crauwels H; Patel P; Cutrell A; Smith KY; Vandermeulen K; Birmingham E; St Clair M; Spreen WR; D'Amico R
    Lancet HIV; 2021 Nov; 8(11):e668-e678. PubMed ID: 34656207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotypic correlates of resistance to the HIV-1 strand transfer integrase inhibitor cabotegravir.
    Rhee SY; Parkin N; Harrigan PR; Holmes S; Shafer RW
    Antiviral Res; 2022 Dec; 208():105427. PubMed ID: 36191692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
    Orkin C; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Overton ET; Girard PM; Oka S; Walmsley S; Bettacchi C; Brinson C; Philibert P; Lombaard J; St Clair M; Crauwels H; Ford SL; Patel P; Chounta V; D'Amico R; Vanveggel S; Dorey D; Cutrell A; Griffith S; Margolis DA; Williams PE; Parys W; Smith KY; Spreen WR
    N Engl J Med; 2020 Mar; 382(12):1124-1135. PubMed ID: 32130806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials.
    Elliot ER; Polli JW; Patel P; Garside L; Grove R; Barnett V; Roberts J; Byrapuneni S; Crauwels H; Ford SL; Van Solingen-Ristea R; Birmingham E; D'Amico R; Baugh B; van Wyk J
    J Infect Dis; 2024 Jul; 230(1):e34-e42. PubMed ID: 39052748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
    Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
    Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabotegravir: a novel HIV integrase inhibitor combined with rilpivirine as the first long-acting injectable program for the treatment of HIV infection.
    Zeuli JD; Rivera CG; Smith BL; Otto A; Temesgen Z
    Drugs Today (Barc); 2022 Dec; 58(12):555-576. PubMed ID: 36651065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.
    Cutrell AG; Schapiro JM; Perno CF; Kuritzkes DR; Quercia R; Patel P; Polli JW; Dorey D; Wang Y; Wu S; Van Eygen V; Crauwels H; Ford SL; Baker M; Talarico CL; Clair MS; Jeffrey J; White CT; Vanveggel S; Vandermeulen K; Margolis DA; Aboud M; Spreen WR; van Lunzen J
    AIDS; 2021 Jul; 35(9):1333-1342. PubMed ID: 33730748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Features of HIV-1 Integrase Sub-Subtype A6 Predominant in Russia and Predicted Susceptibility to INSTIs.
    Kirichenko A; Lapovok I; Baryshev P; van de Vijver DAMC; van Kampen JJA; Boucher CAB; Paraskevis D; Kireev D
    Viruses; 2020 Jul; 12(8):. PubMed ID: 32752001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
    Swindells S; Andrade-Villanueva JF; Richmond GJ; Rizzardini G; Baumgarten A; Masiá M; Latiff G; Pokrovsky V; Bredeek F; Smith G; Cahn P; Kim YS; Ford SL; Talarico CL; Patel P; Chounta V; Crauwels H; Parys W; Vanveggel S; Mrus J; Huang J; Harrington CM; Hudson KJ; Margolis DA; Smith KY; Williams PE; Spreen WR
    N Engl J Med; 2020 Mar; 382(12):1112-1123. PubMed ID: 32130809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
    Orkin C; Schapiro JM; Perno CF; Kuritzkes DR; Patel P; DeMoor R; Dorey D; Wang Y; Han K; Van Eygen V; Crauwels H; Ford SL; Latham CL; St Clair M; Polli JW; Vanveggel S; Vandermeulen K; D'Amico R; Garges HP; Zolopa A; Spreen WR; van Wyk J; Cutrell AG
    Clin Infect Dis; 2023 Nov; 77(10):1423-1431. PubMed ID: 37340869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-treatment integrase inhibitor resistance is uncommon in antiretroviral therapy-naive individuals with HIV-1 subtype A1 and D infections in Uganda.
    McCluskey SM; Kamelian K; Musinguzi N; Kigozi S; Boum Y; Bwana MB; Muzoora C; Brumme ZL; Carrington M; Carlson J; Foley B; Hunt PW; Martin JN; Bangsberg DR; Harrigan PR; Siedner MJ; Haberer JE; Lee GQ
    AIDS; 2021 Jun; 35(7):1083-1089. PubMed ID: 33635845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection.
    Chounta V; Snedecor SJ; Wu S; Van de Velde N
    BMC Infect Dis; 2022 May; 22(1):428. PubMed ID: 35508986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study.
    Garris CP; Czarnogorski M; Dalessandro M; D'Amico R; Nwafor T; Williams W; Merrill D; Wang Y; Stassek L; Wohlfeiler MB; Sinclair GI; Mena LA; Thedinger B; Flamm JA; Benson P; Spreen WR
    J Int AIDS Soc; 2022 Sep; 25(9):e26006. PubMed ID: 36097674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.